生长激素治疗中老年男性骨质疏松的研究进展

骨质疏松是中老年人群中的一种常见病,是中老年人不可避免的一种骨质老化现象。目前全球骨质疏松患者超过1亿人,国内对7省市4.87万人的调查结果显示,60岁以上人群骨质疏松症的患病率为22.6%。骨质疏松可以导致骨折,可明显增加老年人病死率和致残率,调查显示,骨质疏松性骨折后1年内男性死亡率(31﹪)是女性(17﹪)的2倍。有研究表明中老年骨质疏松与生长激素分泌减少有一定关系,小剂量补充治疗后骨骼密度明显增加。本文就生长激素与中老年男性骨质疏松的关系及其补充治疗的可能作用机制作一综述。

Research progress of growth hormone in the treatment of osteoporosis in senile male patients

Osteoporosis is a common disease and an inevitable phenomenon of bone aging in the elderly population. Currently, more than 100 million people suffer from osteoporosis around the world. A survey covering 4.87 million people in 7 provinces in China shows that, the prevalence of osteoporosis is 22.6% in the population over 60 years old. Osteoporosis can lead to fractures, which can increase the mortality and morbidity in the elderly significantly. Surveys have also revealed that the mortality rate of men (31%) with osteoporotic fractures in one year is almost twice compared to the rate in women (17%). Studies have shown that the senile osteoporosis has a certain relationship with the reduced secretion of growth hormone (GH). And low-dose supplementation of GH can significantly increase the bone mineral density. This paper reviews the relationship between GH and osteoporosis in elderly men and the possible mechanism of the complementary treatment.